BMJ open sport & exercise medicine · 2026
Exertional rhabdomyolysis: clinical features, management, complications and prediction of acute kidney injury.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vangstad Marie, Kro Birkeland Jon Arne, Gulsvik Anne Kristine, Ervik Ragnhild Louise, Oftebro Ingrid, Brekke Fredrik Barth, Akkouh Omar Ahmed, Jacobsen Dag, Bjornaas Mari Asphjell
Аннотация
OBJECTIVES: To describe the clinical course and complications of exertional rhabdomyolysis, compare inpatient and outpatient management, and evaluate admission markers of acute kidney injury (AKI).
METHODS: Prospective, multicentre study with consecutive inclusion of patients with rhabdomyolysis (creatine kinase (CK) ≥5000 U/L and/or myoglobin ≥1000 ng/mL) with exercise as the precipitating factor, presenting to the emergency departments of four hospitals in Oslo and Akershus, Norway (2019-2022). Management followed usual care. Primary outcome was AKI, defined by Kidney Disease: Improving Global Outcomes criteria.
RESULTS: We included 136 patients with exertional rhabdomyolysis (median age 28 years, 55% male), mainly after strength training (106, 78%); 62 (46%) were managed as inpatients and 74 (54%) as outpatients. Management was similar in both groups, consisting of fluids, serial blood tests, with a median follow-up of 3 days. Complications were rare and no outpatients required escalation to inpatient care. Five (4%) patients developed AKI (median peak creatinine 217 µmol/L, 132-410). Other major complications (severe electrolyte disturbances and compartment syndrome) occurred only in those with AKI.All patients who developed AKI had serum creatinine above the normal reference range at admission, though a few patients with elevated creatinine did not develop AKI (95% specificity). The myoglobin-to-CK ratio (≥0.48) performed best among muscle injury biomarkers and might serve as a supportive high-risk marker (99% specificity).
CONCLUSION: No patient with a normal admission creatinine developed AKI in this cohort, supporting outpatient management as a safe option for otherwise healthy individuals when admission creatinine is within the reference range, provided follow-up is ensured.
TRIAL REGISTRATION NUMBER: NCT04118608.
METHODS: Prospective, multicentre study with consecutive inclusion of patients with rhabdomyolysis (creatine kinase (CK) ≥5000 U/L and/or myoglobin ≥1000 ng/mL) with exercise as the precipitating factor, presenting to the emergency departments of four hospitals in Oslo and Akershus, Norway (2019-2022). Management followed usual care. Primary outcome was AKI, defined by Kidney Disease: Improving Global Outcomes criteria.
RESULTS: We included 136 patients with exertional rhabdomyolysis (median age 28 years, 55% male), mainly after strength training (106, 78%); 62 (46%) were managed as inpatients and 74 (54%) as outpatients. Management was similar in both groups, consisting of fluids, serial blood tests, with a median follow-up of 3 days. Complications were rare and no outpatients required escalation to inpatient care. Five (4%) patients developed AKI (median peak creatinine 217 µmol/L, 132-410). Other major complications (severe electrolyte disturbances and compartment syndrome) occurred only in those with AKI.All patients who developed AKI had serum creatinine above the normal reference range at admission, though a few patients with elevated creatinine did not develop AKI (95% specificity). The myoglobin-to-CK ratio (≥0.48) performed best among muscle injury biomarkers and might serve as a supportive high-risk marker (99% specificity).
CONCLUSION: No patient with a normal admission creatinine developed AKI in this cohort, supporting outpatient management as a safe option for otherwise healthy individuals when admission creatinine is within the reference range, provided follow-up is ensured.
TRIAL REGISTRATION NUMBER: NCT04118608.